Volume | 40,045 |
|
|||||
News | - | ||||||
Day High | 0.4165 | Low High |
|||||
Day Low | 0.395 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dermata Therapeutics Inc | DRMA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.3971 | 0.395 | 0.4165 | 0.4108 | 0.3931 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
79 | 40,045 | $ 0.407013 | $ 16,299 | - | 0.3701 - 3.93 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:15:21 | formt | 3,000 | $ 0.4165 | USD |
Dermata Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.31M | 3.19M | - | 0 | -9.61M | -3.01 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dermata Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DRMA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.41 | 0.4426 | 0.3801 | 0.4046111 | 112,990 | 0.0065 | 1.59% |
1 Month | 0.44 | 0.4624 | 0.3709 | 0.4060304 | 89,123 | -0.0235 | -5.34% |
3 Months | 0.5825 | 0.89 | 0.3701 | 0.6171631 | 851,164 | -0.166 | -28.50% |
6 Months | 1.08 | 1.12 | 0.3701 | 0.638415 | 511,313 | -0.6635 | -61.44% |
1 Year | 1.32 | 3.93 | 0.3701 | 1.86 | 897,925 | -0.9035 | -68.45% |
3 Years | 92.80 | 111.20 | 0.3701 | 10.01 | 858,439 | -92.38 | -99.55% |
5 Years | 92.80 | 111.20 | 0.3701 | 10.01 | 858,439 | -92.38 | -99.55% |
Dermata Therapeutics Description
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. |